Oops
Oops- this event doesn't have a website associated with it.
But don't worry, the Aguettant team will still be there to showcase Dzuveo®.
Fill in the form below for more information on this event, or anything else.
Contact us for more information on this event
Simply fill in the form, and an Aguettant team member will get in touch shortly.
3 steps to Dzuveo®
sublingual sufentanil tablets
02
Sign up for our emails to receive the latest news about Dzuveo®, including updates on new clinical data, support tools and product availability.
Safety information
Dzuveo is to be administered by a healthcare professional in a medically monitored setting only. A medically monitored setting must have equipment and personnel trained to detect and manage hypoventilation, and availability of supplemental oxygen and opioid antagonists, such as naloxone. Dzuveo should only be prescribed and administered by healthcare professionals who are experienced in the management of opioid therapy; particularly opioid adverse reactions, such as respiratory depression